Navigation Links
WorldHeart Notified of TSX Delisting Review

OAKLAND, Calif., May 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) World Heart Corporation ("WorldHeart" or the "Corporation") announced that the Toronto Stock Exchange ("TSX") issued a Bulletin today advising it is reviewing the eligibility for continued listing on the TSX of the common shares of WorldHeart under sections 709 and 710(a) of the TSX Company Manual. This review relates to the Company's financial condition and operating results, more specifically whether the Company can continue as a going concern. Further to the TSX's Remedial Review Process, WorldHeart has been granted 30 days in which to demonstrate compliance with these requirements. The Company is also permitted to make submissions regarding this matter at a hearing scheduled to be held on June 5, 2008. If the Company cannot demonstrate that it meets all TSX requirements on or before June 11, 2008, the Company's common shares will be delisted 30 days from such date.

The notice also states that if at anytime, TSX becomes aware of additional negative developments such that the continued trading or listing of a Company's securities is contrary to public interest, an expedited review will be initiated.

On the same day, WorldHeart received a notice from the TSX that the Company improperly disseminated material information by failing to issue a news release immediately. The news release was circulated on May 9, 2008, when it should have been circulated on May 8, 2008 at the same time the Company filed its public disclosure with the US and Canadian securities commissions. The Company's management has made policy changes to ensure timely disclosure of material events, as required under section 4(b) of the TSX Company Manual.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB for the year ended December 31, 2007.

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Vion Pharmaceuticals to Appeal Nasdaq Delisting
3. QMed, Inc. Receives NASDAQ Delisting Letter
4. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
5. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
6. Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response
7. Review of cervical cancer screening program shows effectiveness and room for improvement
8. Systematic Review of Patient-Reported Outcomes (PROs) Can Reduce Cost of Cancer Care
9. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
10. Review Urges Aggressive MRSA Screening for Health Workers
11. ACC Calls on FDA to Update Review of Bisphenol A
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... choice for innovative, patient centered orthopedic care. Led by John Vitolo, M.D., ... injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in ... can visit Dr. Margulies to experience the best available orthodontic experience in the area. ... "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the ...
(Date:11/30/2015)... ... 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene ... of Dental Medicine in 1935. His father graduated from NYU School of Dentistry ... as well as their commitment and passion to the Practice of Dentistry. Continuing ...
(Date:11/30/2015)... ALEXANDRIA, VA (PRWEB) , ... November 30, 2015 ... ... American Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that ... centers managed almost 3 million cases, over two million of which were human ...
(Date:11/30/2015)... ... November 30, 2015 , ... Two years ago, Debbie Gregory, the ... David Lynch Foundation, learning Transcendental Meditation (TM). After encouraging a number of veterans ... so that she could talk the talk. , TM is becoming one of the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... LAKE CITY , Nov. 30, 2015 Booth ... (NYSE: VAR ) will exhibit a broader array of ... of the Radiological Society of North America ... Varian exhibit at the meeting will feature X-ray components "At ... CT tube, a line of products from Varian,s Claymount brand, ...
(Date:11/30/2015)... Belgium , Nov. 30, 2015   VolitionRx Limited ... developing blood-based diagnostic tests for a broad range of cancer ... at the LD Micro Conference, which will be held December ... Attending from VolitionRx will be David Kratochvil , ... Vice President of Investor Relations. ® blood-based ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology: